Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Trillium Therapeutics -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (230)	11/15/2018 12:40:25 PM
From: tuck	1 Recommendation Recommended By ghmm Read Replies (1) \| Respond to of 294

Further color on the CD47 antibody+rituxan combo. Note that the TRIL's advantage in RBC binding seems to have been nullified via priming and maintenance dosing with F59: Anti-CD47 Antibody Plus Rituximab Demonstrates Efficacy in Half of Patients With Relapsed/Refractory NHL Now, further depth, as it appears the germline source of the DLBCL really matters, and likely leads to good efficacy with a companion diagnostic to to find the right patients and then triple composing with CHOP (h/t to Dr. Paul DeSantis for the dig): Expression Defines the Efficacy of Rituximab in Non-Germinal Center B-Cell (non-GCB) Diffuse Large B-Cell Lymphoma Ways for competition to keep chipping away at TRIL keep showing up. Cheers, Tuck